More strikingly, systemic administration of stimulator of interferon genes (STING) agonist-loaded IGFBP7-sEVs outperformed direct intratumoral injection of free STING agonist: the glioma microenvironment (GME) was extensively remodeled and antigen-presenting capacity of myeloid cells was markedly enhanced. Here, IGFBP7 is linked to central nervous system cancer.